Direct cell-to-cell Interaction (2D) |
VSMCs, monocytes, ECs |
To study the effect of diseased conditions (M-CSF, diabetic, or vascular injury) on atherosclerotic development, including macrophage activation/adhesion to VSMC, or SMC phenotype switch |
(96–98) |
|
Monocytes, HUVECs, bacterium |
To study the impact of bacterial infection on atherosclerosis development (inflammation and EC apoptosis) |
(99–105) |
|
ECs, THP-1s |
To evaluate potential atherosclerosis treatment |
(106–108) |
In-direct Transwell Co-culture (2D) |
SMCs, THP-1s |
To study the significance of physical contact between SMC and monocyte for atherosclerosis development |
(109) |
|
SMCs, ECs, THP-1s |
To study the interactions between different cell types and their effects on atherogenesis. |
(16, 110–112) |
Cell Sheet (2D) (Decellularized ECM) |
ECs and SMCs differentiated from BMCs; fibroblast, SMCs, ECs, chondrocytes |
To mimic the native ECM component to improve vascular cell spreading and proliferation. |
(117–121) |
Cell Sheet (Polymer Scaffold) |
SMCs |
To partially mimic arterial structure |
(122–124) |
Microfluidic Chip (2D) |
ECs (endothelium-on-a-chip), THP-1s |
To observe endothelial response, inflammation, and interaction with monocytes during atherosclerosis. |
(127–130, 132, 133) |
|
|
To evaluate the effect of nanomedicine on dysfunctional endothelium |
(128, 134) |
|
Multi-layer including SMCs, ECs, and foam cells |
To study the mechanism of atorvastatin under the atherosclerotic condition |
(131) |
Spheroid (3D) |
Foam cells |
To evaluate therapeutic effects on atherosclerosis |
(150, 151) |
|
SMCs |
To study SMC remodeling during atherosclerosis |
(152, 153) |
|
Myeloid cells, THP-1s, macrophage, dendritic, myofibroblasts |
To emulate late-stage fibroatheroma |
(15) |
Cell-laden Hydrogel Construct (3D) |
ECs, SMCs, monocytes neutrophil in collagen gel |
To mimic early atherosclerosis and study the effect of SMC on monocyte adhesion |
(157, 158) |
|
THP-1s in collagen gel |
To study ECM effect on macrophage behavior under early and late atherosclerosis |
(159) |
|
ECs, SMCs, monocytes |
To study early atherosclerosis development |
(160, 161) |
Tissue-engineered Blood Vessel (3D) |
ECs, fibroblasts, or SMCs (2-layered vessels) |
To study the mechanism of atherogenesis or drug screening |
(165–167) |
|
ECs, monocytes (branched geometry) |
To study the endothelial behavior in the athero-prone region |
(169, 170) |
|
ECs, SMCs, monocytes, fibroblasts |
To mimic key early atherosclerotic plaque features for mechanism study or drug screening |
(18, 21, 171) |
Vessel-on-a-chip (3D) |
ECs, SMCs |
To mimic the natural vascular features on a chip with controlled geometry |
(178–180) |
|
ECs, SMCs, and macrophages |
To emulate atherosclerotic plaque on a chip |
(181–183) |